3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
60
Prostatic Neoplasms
52
Squamous Cell Carcinoma of Head and Neck
43
Carcinoma, Non-Small-Cell Lung
39
Head and Neck Neoplasms
37
Lung Neoplasms
35
Lymphoma
34
Leukemia
22
Brain Neoplasms
20
Central Nervous System Neoplasms
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Glioblastoma
18
Uterine Cervical Neoplasms
17
Sarcoma
17
Rectal Neoplasms
17
Lymphoma, Follicular
16
Esophageal Squamous Cell Carcinoma
16
Esophageal Neoplasms
15
Lymphoma, Large B-Cell, Diffuse
14
Hodgkin Disease
14
Burkitt Lymphoma
14
Adenocarcinoma of Lung
13
Oligodendroglioma
12
Lymphoma, Non-Hodgkin
12
Neoplasm Metastasis
11
Astrocytoma
11
Rhabdomyosarcoma
10
Lymphoma, Large-Cell, Immunoblastic
10
Neuroblastoma
9
Nasopharyngeal Carcinoma
9
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Radiotherapy
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled